The erythema Q-score, an imaging biomarker for redness in skin inflammation.
biomarkers
inflammation
inflammatory skin diseases
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
15
09
2020
received:
29
04
2020
accepted:
17
10
2020
pubmed:
29
10
2020
medline:
25
2
2022
entrez:
28
10
2020
Statut:
ppublish
Résumé
Physician rating of cutaneous erythema is central to clinical dermatological assessment as well as quantification of outcome measures in clinical trials in a number of dermatologic conditions. However, issues with inter-rater reliability and variability in the setting of higher Fitzpatrick skin types make visual erythema assessment unreliable. We developed and validated a computer-assisted image-processing algorithm (EQscore) to reliably quantify erythema (across a range of skin types) in the dermatology clinical setting. Our image processing algorithm evaluated erythema based upon green light suppression differentials between affected and unaffected skin. A group of four dermatologists used a 4-point Likert scale as a human evaluation of similar erythematous patch tests. The algorithm and dermatologist scores were compared across 164 positive patch test reactions. The intra-class correlation coefficient of groups and the correlation coefficient between groups were calculated. The EQscore was validated on and independent image set of psoriasis, minimal erythema dose testing and steroid-induced blanching images. The reliability of the erythema quantification method produced an intra-class correlation coefficient of 0.84 for the algorithm and 0.67 for dermatologists. The correlation coefficient between groups was 0.85. The EQscore demonstrated high agreement with clinical scoring and superior reliability compared with clinical scoring, avoiding the pitfalls of erythema underrating in the setting of pigmentation. The EQscore is easily accessible (http://lab.rockefeller.edu/krueger/EQscore), user-friendly, and may allow dermatologists to more readily and accurately rate the severity of dermatological conditions and the response to therapeutic treatments.
Identifiants
pubmed: 33113259
doi: 10.1111/exd.14224
pmc: PMC8049083
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
377-383Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA240254
Pays : United States
Informations de copyright
© 2020 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd.
Références
J Pharm Pharm Sci. 2008;11(1):160-6
pubmed: 18445371
J Vis Exp. 2013 May 28;(75):e50175
pubmed: 23748556
J Drugs Dermatol. 2006 Oct;5(9):853-8
pubmed: 17039650
Dermatol Ther. 2009 May-Jun;22(3):191-8
pubmed: 19453342
J Allergy Clin Immunol Pract. 2015 May-Jun;3(3 Suppl):S1-39
pubmed: 25965350
Clin Exp Dermatol. 2009 Jun;34(4):492-4
pubmed: 19175618
Skin Res Technol. 2000 Nov;6(4):230-238
pubmed: 11428962
J Am Acad Dermatol. 2014 Oct;71(4):760-3
pubmed: 24999270
Dermatitis. 2013 Jan-Feb;24(1):7-9
pubmed: 23340393
Contact Dermatitis. 1996 Jul;35(1):1-10
pubmed: 8896947
J Dtsch Dermatol Ges. 2013 Jul;11(7):607-19; quiz 620-1
pubmed: 23802782
Exp Dermatol. 2021 Mar;30(3):377-383
pubmed: 33113259
Contact Dermatitis. 2015 Jan;72(1):2-10
pubmed: 25348820
Skin Res Technol. 2008 Feb;14(1):26-34
pubmed: 18211599
Photodermatol Photoimmunol Photomed. 2013 Aug;29(4):190-5
pubmed: 23815351
Br J Dermatol. 1998 Nov;139(5):811-4
pubmed: 9892946
Australas J Dermatol. 2018 May;59(2):101-107
pubmed: 28247404
Int J Womens Dermatol. 2015 Aug 06;1(3):150-154
pubmed: 28491979
Indian J Dermatol Venereol Leprol. 2006 Jul-Aug;72(4):315-21
pubmed: 16880586
J Med Eng Technol. 2009;33(7):516-24
pubmed: 19639508
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1696-700
pubmed: 24456040